Clinical Trial Update: Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating healthy donor fecal microbiota transplant in combination with pembrolizumab for relapsed/refractory PD-L1 positive non-small cell lung …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Healthy donor fecal microbiota transplant (hdFMT) (fecal microbiota transplant)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Diwakar Davar | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: RECRUITING